Valuation: Profound Medical Corp

Market Cap 355M 255M 221M 207M 189M 24.31B 361M 2.44B 951M 12.17B 956M 936M 40.59B P/E 2026 *
-8.11x
P/E 2027 * -11.9x
Enterprise Value 355M 255M 221M 207M 189M 24.31B 361M 2.44B 951M 12.17B 956M 936M 40.59B EV / Sales 2026 *
9.81x
EV / Sales 2027 * 5.97x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
President 44 2024-11-06
Director of Finance/CFO 58 2022-03-02
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%+2.95%+23.17%+10.51% 223B
-0.96%+1.85%-2.62%-20.81% 145B
-0.39%+6.98%-17.11%+31.05% 142B
-0.09%+4.19%-49.89%+0.07% 74.52B
-0.64%+3.54%+19.05%+14.84% 53.63B
+0.03%-0.15%-16.01%-17.13% 50.14B
+0.29%+5.07%+23.45%+17.25% 41.87B
-0.06%+4.06%+40.12%+44.23% 40.89B
+1.28%+4.08%-2.85%+1.92% 32.65B
Average -0.18%+4.23%+1.92%+9.10% 89.23B
Weighted average by Cap. -0.55%+4.56%+1.73%+7.81%

Financials

2026 *2027 *
Net sales 36.22M 25.98M 22.52M 21.11M 19.25M 2.48B 36.8M 249M 97.03M 1.24B 97.53M 95.42M 4.14B 59.46M 42.65M 36.97M 34.65M 31.6M 4.07B 60.41M 408M 159M 2.04B 160M 157M 6.8B
Net income -44.08M -31.62M -27.41M -25.69M -23.43M -3.02B -44.78M -303M -118M -1.51B -119M -116M -5.04B -31.27M -22.43M -19.44M -18.22M -16.62M -2.14B -31.77M -215M -83.77M -1.07B -84.2M -82.37M -3.57B
Net Debt - -
Logo Profound Medical Corp
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-